Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor
暂无分享,去创建一个
D. Olive | D. Blaise | R. Devillier | C. Fauriat | C. Chabannon | É. Vivier | S. Guia | S. Ugolini | G. Venton | B. Mfarrej | B. Calmels | M. Taha
[1] P. Thall,et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.
[2] Clara Di Vito,et al. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies , 2019, Front. Immunol..
[3] T. Nakamaki,et al. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia , 2019, International journal of molecular sciences.
[4] U. Germing,et al. Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment , 2019, International journal of molecular sciences.
[5] D. Blaise,et al. Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells , 2018, British journal of haematology.
[6] O. Lantz,et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells , 2018, Cell.
[7] É. Vivier,et al. Natural killer cells and other innate lymphoid cells in cancer , 2018, Nature Reviews Immunology.
[8] J. Esteve,et al. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation , 2018, Bone Marrow Transplantation.
[9] J. Wagner,et al. Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] É. Vivier,et al. Activating and inhibitory receptors expressed on innate lymphoid cells , 2018, Seminars in Immunopathology.
[11] S. Bicciato,et al. The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation , 2018, Haematologica.
[12] Depei Wu,et al. IL‐12/IL‐18‐preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation , 2018, European journal of immunology.
[13] M. Davids,et al. Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. , 2018, Blood.
[14] P. Parham,et al. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. , 2018, Blood.
[15] G. Oliveira,et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. , 2018, Blood.
[16] K. Rezvani,et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. , 2017, Blood.
[17] A. Cerwenka,et al. Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation , 2017, Front. Immunol..
[18] R. Negrin,et al. Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation , 2017, Front. Immunol..
[19] D. Blaise,et al. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML , 2017, Bone Marrow Transplantation.
[20] J. Esteve,et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT , 2016, Bone Marrow Transplantation.
[21] F. Claas,et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia , 2016, Science Translational Medicine.
[22] L. Castagna,et al. Donor lymphocyte infusion after allogeneic stem cell transplantation. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[23] H. Kolb,et al. Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation , 2016, Bone Marrow Transplantation.
[24] A. Tosti,et al. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells , 2016, Haematologica.
[25] A. Schwarer,et al. NK cell maturation to CD56(dim) subset associated with high levels of NCRs overrides the inhibitory effect of NKG2A and recovers impaired NK cell cytolytic potential after allogeneic hematopoietic stem cell transplantation. , 2016, Leukemia research.
[26] H. Putter,et al. Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion , 2016, Haematologica.
[27] A. Cerwenka,et al. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy , 2015, Cytotherapy.
[28] S. Granjeaud,et al. Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[29] P. Chevallier,et al. Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial , 2015, Haematologica.
[30] J. Scarisbrick,et al. A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent , 2015, Bone Marrow Transplantation.
[31] R. Bouabdallah,et al. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[32] H. Vié,et al. ADAM17-Mediated Shedding of FcγRIIIA on Human NK Cells: Identification of the Cleavage Site and Relationship with Activation , 2014, The Journal of Immunology.
[33] Bin Zhang,et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). , 2013, Blood.
[34] Bin Zhang,et al. NK cell CD 16 surface expression and function is regulated by a disintegrin and metalloprotease-17 ( ADAM 17 ) , 2013 .
[35] Elaine Coustan-Smith,et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. , 2012, Cytotherapy.
[36] Eric Vivier,et al. Targeting natural killer cells and natural killer T cells in cancer , 2012, Nature Reviews Immunology.
[37] Y. Kerdiles,et al. Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor , 2011, Proceedings of the National Academy of Sciences.
[38] Baptiste N. Jaeger,et al. Confinement of Activating Receptors at the Plasma Membrane Controls Natural Killer Cell Tolerance , 2011, Science Signaling.
[39] R. Negrin,et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. , 2010, Blood.
[40] É. Vivier,et al. Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo , 2009, Proceedings of the National Academy of Sciences.
[41] M. Berg,et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. , 2009, Cytotherapy.
[42] D. Campana,et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.
[43] J. Schold,et al. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease , 2008, Haematologica.
[44] Eric Vivier,et al. Functions of natural killer cells , 2008, Nature Immunology.
[45] M. Labopin,et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Marcela R. Uribe,et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia , 2007, Leukemia.
[47] G. Ledderose,et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[49] G. Gastl,et al. Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. , 2003, Immunobiology.
[50] Katia Perruccio,et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.
[51] L. Moretta,et al. NKp44, a Novel Triggering Surface Molecule Specifically Expressed by Activated Natural Killer Cells, Is Involved in Non–Major Histocompatibility Complex–restricted Tumor Cell Lysis , 1998, The Journal of experimental medicine.
[52] S. Sforzini,et al. The natural killer-related receptor for HLA-C expressed on T cells from CD3+ lymphoproliferative disease of granular lymphocytes displays either inhibitory or stimulatory function. , 1996, Blood.
[53] A Ferrant,et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.